Medunik USA maintains its commitment to the rare disease market by ensuring consistent access to Pheburane for patients managing urea cycle disorders.
Medunik USA reaffirms continued availability of Pheburane for UCD patients, a neutral operational announcement with no financial guidance.
Medunik USA, a division of Duchesnay Pharmaceutical Group, confirms the continued supply of Pheburane for patients diagnosed with urea cycle disorders. The announcement serves to stabilize the treatment landscape for those relying on the orphan drug for rare disease management.
The company is reaffirming the continued availability of Pheburane for patients suffering from urea cycle disorders.